SG11201810471YA - T cell expansion - Google Patents

T cell expansion

Info

Publication number
SG11201810471YA
SG11201810471YA SG11201810471YA SG11201810471YA SG11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA SG 11201810471Y A SG11201810471Y A SG 11201810471YA
Authority
SG
Singapore
Prior art keywords
international
cells
virus
london
herencia
Prior art date
Application number
SG11201810471YA
Inventor
Peter Wang
Chunxiao Wu
Original Assignee
Tessa Therapeutics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tessa Therapeutics Pte Ltd filed Critical Tessa Therapeutics Pte Ltd
Publication of SG11201810471YA publication Critical patent/SG11201810471YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111 111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/202478 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C12N 5/0783 (2010.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/EP2016/075644 Published: — with international search report (Art. 21(3)) (22) International Filing Date: 25 October 2016 (25.10.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/340,605 24 May 2016 (24.05.2016) US 15/290,230 11 October 2016 (11.10.2016) US (71) Applicant: TESSA THERAPEUTICS PTE LTD [SG/SG]; 46 Kim Yam Road, #01-14 The Herencia, Singa- pore 239351 (SG). (71) Applicant (for LS only): CLEGG, Richard Ian [GB/GB]; City Tower, 40 Basinghall Street, London, Greater London EC2V 5DE (GB). (72) Inventors: WANG, Peter; c/o Tessa Therapeutics Pte = Ltd, 46 Kim Yam Road, #01-14, The Herencia, Singapore = 239351 (SG). WU, Chunxiao; c/o Tessa Therapeutics Pte _ Ltd, 46 Kim Yam Road, #01-14, The Herencia, Singapore 239351 = (SG). (74) Agent: CLEGG, Richard et al.; Mewburn Ellis LLP, = City Tower, 40 Basinghall Street, London, Greater London = EC2V 5DE (GB). _ = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, = KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, = — MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, _ = PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, = SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, = TZ, ZA, ZM, ZW. UA, UG, US, UZ, VC, VN, = (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, _ TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, GC IN I I - (54) Title: T CELL EXPANSION ei 0 (57) : A method for generating or expanding a population of T cells specific for a virus by a method comprising: stimulating T ei ----. cells by culture in the presence of antigen presenting cells (APCs) presenting a peptide of the virus, wherein at least 10% of the media in IN which the cells are cultured is conditioned media obtained from a stimulation culture comprising T cells and APCs presenting a peptide © of the virus. Also disclosed are methods for accelerating the rate of expansion of a virus-specific T cell population, and methods for N treating or preventing diseases or disorders using the generated or expanded T cell population. O
SG11201810471YA 2016-05-24 2016-10-25 T cell expansion SG11201810471YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340605P 2016-05-24 2016-05-24
US15/290,230 US10052372B2 (en) 2016-05-24 2016-10-11 T cell expansion
PCT/EP2016/075644 WO2017202478A1 (en) 2016-05-24 2016-10-25 T cell expansion

Publications (1)

Publication Number Publication Date
SG11201810471YA true SG11201810471YA (en) 2018-12-28

Family

ID=57886334

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810471YA SG11201810471YA (en) 2016-05-24 2016-10-25 T cell expansion

Country Status (12)

Country Link
US (2) US10052372B2 (en)
EP (1) EP3265555B1 (en)
JP (1) JP2019520061A (en)
KR (1) KR20190013831A (en)
CN (1) CN109563483A (en)
DK (1) DK3265555T3 (en)
ES (1) ES2742215T3 (en)
HK (1) HK1250378B (en)
PT (1) PT3265555T (en)
SG (1) SG11201810471YA (en)
TW (1) TWI660970B (en)
WO (1) WO2017202478A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142358A1 (en) * 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CA3023221A1 (en) 2016-05-05 2017-11-09 Southwest Research Institute Three-dimensional bioreactor for cell expansion and related applications
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
CN110710252B (en) * 2017-05-06 2023-06-16 Lg电子株式会社 D2D operation method of terminal in wireless communication system and terminal using the same
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
AU2019346419B2 (en) 2018-09-24 2023-08-17 Southwest Research Institute Three-dimensional bioreactors
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
EP4308733A1 (en) 2021-03-18 2024-01-24 The Broad Institute, Inc. Compositions and methods for characterizing lymphoma and related conditions
WO2022232797A2 (en) 2021-04-27 2022-11-03 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors
WO2023198744A1 (en) 2022-04-13 2023-10-19 Tessa Therapeutics Ltd. Therapeutic t cell product

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
AU1220599A (en) 1997-11-14 1999-06-07 Hemosol Inc. Method for the production and use of dendritic cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
EP2698430A3 (en) * 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
WO2013088114A1 (en) * 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Also Published As

Publication number Publication date
ES2742215T3 (en) 2020-02-13
DK3265555T3 (en) 2019-08-12
EP3265555B1 (en) 2019-05-22
EP3265555A1 (en) 2018-01-10
KR20190013831A (en) 2019-02-11
US10052372B2 (en) 2018-08-21
PT3265555T (en) 2019-09-04
TW201741330A (en) 2017-12-01
US20190269768A1 (en) 2019-09-05
HK1250378B (en) 2020-05-08
TWI660970B (en) 2019-06-01
US20170028042A1 (en) 2017-02-02
CN109563483A (en) 2019-04-02
JP2019520061A (en) 2019-07-18
WO2017202478A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
SG11201810471YA (en) T cell expansion
SG11201811048UA (en) Single-cell transcript sequencing
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201810605UA (en) Selectively altering microbiota for immune modulation
SG11201806988UA (en) Improved differentiation method
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201909949XA (en) Targeted immunotolerance
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201808125RA (en) Methods for solid tumor treatment
SG11201807487WA (en) Generation of midbrain-specific organoids from human pluripotent stem cells
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201810430WA (en) Heater assembly for an aerosol-generating system
SG11201806453TA (en) Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201806284TA (en) Low pressure separator having an internal divider and uses therefor
SG11201808306PA (en) Treatment of cancer with tg02
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809594WA (en) Nicotine particles and compositions
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201900058YA (en) Method of generating mesenchymal stem cells and uses thereof